Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

NCT03841747 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding restrictions

Conditions

Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Paclitaxel

Sponsor

Queen Mary University of London

Collaborators

[object Object]
[object Object]